Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Afamitresgene autoleucel (OTHER 02067) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 6, 2026 , from http://ppman.hank.ai/transparency/procedure/02067/by-state?code_type=OTHER
“Afamitresgene autoleucel (OTHER 02067) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/02067/by-state?code_type=OTHER. Accessed
November 6, 2026 .
“Afamitresgene autoleucel (OTHER 02067) by State,” HANK Price Transparency ,
accessed November 6, 2026 ,
http://ppman.hank.ai/transparency/procedure/02067/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
02067 — Afamitresgene Autoleucel
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$800,342
National median
$709,924 – $818,965
IQR (p25 – p75)
4
hospitals filing
4
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 02067 (OTHER), with interquartile range
State Median p25 p75
NH $837,933 $831,553 $844,313
TX $800,342 $800,342 $800,342
CA $679,785 $679,785 $679,785
CO $100,000 $100,000 $100,000